Skip to main content
Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc. — Investor Relations & Filings

Ticker · CODX ISIN · US1897631057 LEI · 549300Z1JPESYWFM1R93 US Manufacturing
Open in API
Filings indexed 343 across all filing types
Latest filing 2026-05-28 Capital/Financing Update
Country US United States of America
Listing US CODX

About Co-Diagnostics, Inc.

https://codiagnostics.com/

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies. The company's core platform is centered on its patented Co-Primers technology, a unique molecular configuration that enhances Polymerase Chain Reaction (PCR) performance by significantly reducing the formation of primer dimers, a primary cause of inaccurate results. This innovation enables the creation of more sensitive and specific diagnostic tests, minimizing false positives and false negatives. Co-Diagnostics provides a range of solutions targeting infectious diseases. Its product portfolio includes reagents for laboratory use, research-use-only (RUO) applications, and vector control. The company is also developing the Co-Dx PCR platform, an integrated system designed to bring rapid, real-time PCR testing to point-of-care and at-home settings, aiming to democratize access to molecular diagnostics.

Recent filings

Filing Released Lang Actions
S-3
Capital/Financing Update Classification · 89% confidence The document is a Form S-3 registration statement/prospectus filed with the U.S. SEC to register 4,942,341 shares of common stock for resale by selling stockholders. It details the terms of the share offering and associated financing activity. This is not a proxy or management disclosure, nor an annual or quarterly report. It is a capital markets filing concerning a securities offering and changes to the company’s capital structure. Therefore it best fits the Capital/Financing Update category (CAP).
2026-05-28 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Current Report on Form 8-K filed with the SEC, describing the Company’s entry into a material definitive agreement for a private placement, issuance of shares and warrants, and related financing terms. This is a fundraising/capital structure update rather than an earnings release, management discussion, or legal proceeding. Therefore, it falls under Capital/Financing Update.
2026-05-21 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings
2026-05-14 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-11 English
S-8 Filing
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Co-Diagnostics, Inc. It is a registration statement under the Securities Act of 1933 for an equity incentive plan. The document includes references to incorporation by reference of other filings such as the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, but this document itself is a registration statement for securities, not a financial report or earnings release. It is a regulatory filing related to securities registration and compliance, not a report of financial results or management discussion. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2026-01-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.